Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.45 |
| ▸ | CHUK | O15111 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4817306 | 0.86 | MET (0.49) | METNUDT1BRAFKDRMAPK14 | |
| SCHEMBL4814426 | 0.83 | KDR (0.54) | METNUDT1BRAFKDRMAPK14 | |
| SCHEMBL4819914 | 0.82 | MET (0.48) | METBRAFKDRMAPK14TNNI3K | |
| SCHEMBL14018113 | 0.81 | MET (0.53) | METBRAFKDRMAPK14TNNI3K | |
| SCHEMBL31061568 | 0.80 | MAP3K7 (0.53) | METNUDT1KDRMAPK14IKBKB | |
| SCHEMBL1591677 | 0.77 | KDR (0.70) | METKDR | |
| SCHEMBL4369928 | 0.75 | MET (0.47) | METBRAFKDRMAPK14TNNI3K | |
| SCHEMBL4363236 | 0.74 | MET (0.47) | METBRAFKDRMAPK14TNNI3K | |
| SCHEMBL14018120 | 0.73 | MET (0.64) | METBRAFKDRMAPK14TNNI3K | |
| SCHEMBL4819121 | 0.73 | IKBKB (0.52) | METIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | claimed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MET 721/4885NUDT1 1017/4885BRAF 55/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | MET 2109/4885NUDT1 1866/4885BRAF 201/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MET 721/4885NUDT1 1017/4885BRAF 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.